Niki BioSolutions annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Niki BioSolutions Stock-Based Compensation Growth & History (NIKI)
Niki BioSolutions's stock-based compensation was $0 for fiscal 2025.
View full Niki BioSolutions company overviewNiki BioSolutions annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | $0 | — |
| 2024 | 2024-12-31 | $0 | −$1.3M | — |
| 2023 | 2023-12-31 | $1.3M | −$381,810 | −23.18% |
| 2022 | 2022-12-31 | $1.6M | −$35,461 | −2.11% |
| 2021 | 2021-12-31 | $1.7M | $203,895 | +13.79% |
| 2020 | 2020-12-31 | $1.5M | −$134,267 | −8.32% |
| 2019 | 2019-12-31 | $1.6M | — | — |
Niki BioSolutions stock-based compensation trends
Over the last five fiscal years, Niki BioSolutions's stock-based compensation decreased from $1.5M to $0, a change of −$1.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Niki BioSolutions source filings ↗